Quoin Pharmaceuticals Reports Third-Quarter Results and Positive QRX003 Interim Data
Quoin Pharmaceuticals reported third-quarter 2026 financial results and positive interim data from its ongoing Phase 2/3 QRX003 study in Netherton syndrome.
Story updates
01:33:33 PM UTC
SquawkNews
Quoin Pharmaceuticals 3Q Loss/Shr 97c >QNRX
01:37:10 PM UTC
SquawkNews
Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target—Announces Private Placement Financing of Up to $50.0 Million with Healthcare-Focused Institu…
01:37:32 PM UTC
SquawkNews
Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton syndrome: four of six participants met the primary endpoint, and the key secondary endpoint was statistically significant. Q3 net loss was approximately $4.9M versus $3.9M a year earlier.Material DetailsContext by AI AnalystThis…